Mesoblast Limited MESO
Updated: 16 Jun 2026
No signal published yet
We already track Mesoblast and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Mesoblast Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Mesoblast free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In June 2026, the company reported that the commercial launch of Ryoncil generated $49 million in revenue during the first half of the fiscal year. Mesoblast also announced plans to submit a Biologics License Application for Revascor in the upcoming quarter.
What Firelda Watch includes for Mesoblast Limited
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Mesoblast Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Mesoblast free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more